Pinchera A, Mariotti S, Vitti P, Marcocci C, Chiovato L, Fenzi G, Santini F
Cattedra di Endocrinologia, Università di Pisa, Italy.
Biochimie. 1989 Feb;71(2):237-45. doi: 10.1016/0300-9084(89)90061-8.
Humoral and cellular immune responses are both involved in autoimmune disorders of the thyroid gland. In the last five years, new substantial data have been obtained on the nature and the expression of thyroid cell surface autoantigens and on the demonstration of the functional heterogeneity of autoantibodies to the thyroid stimulating hormone (TSH) receptor. In the present report, attention will be mainly focused on recent studies carried out in our laboratory. The main autoantigens so far identified include the 'microsomal' antigen, thyroglobulin and the TSH receptor. For many years the 'microsomal' antigen (M) was considered a poorly characterized constituent of the cytoplasm of the thyroid cell. In the last five years, several lines of evidence were provided indicating that M is also well represented on the surface of the follicular cell and is identical to thyroid peroxidase (TPO). The use of anti-TPO monoclonal antibodies, presently available, have confirmed this antigenic identity. Microsomal (anti-TPO) antibodies are very useful markers of autoimmune thyroid disorders and are generally present in Hashimoto's thyroiditis, idiopathic myxedema and Graves' disease. TSH receptor antibodies (TRAb) are present in the sera of patients with Graves' disease. TRAb are able to stimulate thyroid adenylate cyclase and also to mimic TSH in its thyroid growth stimulation. Thus, these antibodies may have a pathogenetic role in goiter formation and in thyroid hyperfunction in Graves' disease. TRAb were also shown to inhibit both TSH binding to its receptor and TSH-stimulated adenylate cyclase activity. Recently TRAb, which inhibited TSH-stimulated adenylate cyclase activity, were found in idiopathic myxedema patients and may be responsible for impairment of thyroid function.(ABSTRACT TRUNCATED AT 250 WORDS)
体液免疫和细胞免疫反应均参与甲状腺自身免疫性疾病。在过去五年中,关于甲状腺细胞表面自身抗原的性质和表达以及针对促甲状腺激素(TSH)受体自身抗体功能异质性的证明,已获得了大量新数据。在本报告中,将主要关注我们实验室最近开展的研究。目前已鉴定出的主要自身抗原包括“微粒体”抗原、甲状腺球蛋白和TSH受体。多年来,“微粒体”抗原(M)被认为是甲状腺细胞质中一种特征不明确的成分。在过去五年中,有几条证据表明M在滤泡细胞表面也有很好的表达,并且与甲状腺过氧化物酶(TPO)相同。目前可用的抗TPO单克隆抗体的使用证实了这种抗原同一性。微粒体(抗TPO)抗体是自身免疫性甲状腺疾病非常有用的标志物,通常存在于桥本甲状腺炎、特发性黏液水肿和格雷夫斯病中。TSH受体抗体(TRAb)存在于格雷夫斯病患者的血清中。TRAb能够刺激甲状腺腺苷酸环化酶,并且在刺激甲状腺生长方面也能模拟TSH。因此,这些抗体可能在格雷夫斯病的甲状腺肿形成和甲状腺功能亢进中起致病作用。TRAb还被证明能抑制TSH与其受体的结合以及TSH刺激的腺苷酸环化酶活性。最近,在特发性黏液水肿患者中发现了抑制TSH刺激的腺苷酸环化酶活性的TRAb,它们可能是甲状腺功能受损的原因。(摘要截短至250字)